The program focuses on pharmacoepidemiology, the clinical pharmacology antipsychotics, particularly risk benefit aspects and the applied clinical pharmacology of antipsychotic switching, physical comorbidities of psychotic disorders (especially metabolic syndrome, and incomplete recovery).